Peptides News and Research

RSS

New England Journal of Medicine publishes Diamyd Medical's antigen-based diabetes therapy study

An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.

3 Feb 2012

Natural resistance to flu could hold key to universal vaccine

Researchers have found that on infecting 41 healthy volunteers with different strains of flu virus, those with higher levels of a specific type of white blood cell were less likely to develop severe illness. Now the team of researchers hopes to mimic the natural resistance shown by some of the volunteers, by creating a vaccine that boosts levels of a particular subset of the 'T-cells'.

1 Feb 2012

Peptides linked with internal flu viral structures can help develop universal vaccine

Researchers at the University of Southampton, University of Oxford and Retroscreeen Virology Ltd have discovered a series of peptides, found on the internal structures of influenza viruses that could lead to the development of a universal vaccine for influenza, one that gives people immunity against all strains of the disease, including seasonal, avian, and swine flu.

1 Feb 2012

HSP40/70 linked to hepatitis C infection

Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication, which can lead to liver cancer and cirrhosis.

31 Jan 2012

Oramed receives Australian patent for core technology in oral delivery of peptides

Marking a major milestone for the Company, Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Australian Patent Office.

25 Jan 2012

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

PolyTherics announces acquisition of WEP

PolyTherics Limited, a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers, a provider of specialty biopolymers for the modification of biological products.

20 Jan 2012

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Smart injectable nanotherapeutics could improve treatment for Type I diabetes

A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas. Although this nanotechnology will need significant additional testing and development before being ready for clinical use, it could potentially improve treatment for Type I diabetes by increasing therapeutic efficacy and reducing side effects.

13 Jan 2012

New lab test quickly identifies bacterium responsible for staph infections

Researchers from the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) have developed a new laboratory test that can rapidly identify the bacterium responsible for staph infections. This new test takes advantage of unique isotopic labeling combined with specific bacteriophage amplification to rapidly identify Staphylococcus aureus.

13 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

Agilent, Integrated Diagnostics partner to improve protein-based LC/MS assays

Agilent Technologies Inc. and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

11 Jan 2012

Study examines impact of maternal obesity on inflammatory responses

A number of different immunological mechanisms ensure the successful establishment and maintenance of pregnancy. Imbalance in these mechanisms is associated with adverse pregnancy outcomes.

11 Jan 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Ipsen, Oncodesign partner to discover and develop LRRK2 kinase inhibitors against PD

Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen, a global specialty-driven pharmaceutical company, announced today that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas.

5 Jan 2012